{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:06Z","timestamp":1781653986341,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic castration-resistant prostate cancer (mCRPC) remains the primary cause of prostate cancer-related mortality. Despite the availability of treatments, the molecular mechanisms underlying tumor invasion and metastasis are not fully understood, highlighting the need for novel therapeutic strategies. In this study, we developed fully human monoclonal antibodies (mAbs) that prevent the proteolytic cleavage of the transforming growth factor-beta (TGF\u03b2) type I receptor (T\u03b2RI) by steric hindrance. This cleavage, mediated by the metalloprotease ADAM17 (a disintegrin and metalloprotease domain 17; also known as TACE), results in the generation of a soluble intracellular domain (T\u03b2RI-ICD) that is translocated to the nucleus of castration-resistant prostate cancer (CRPC) cells and promotes epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. High levels of\n                    <jats:italic>TGFBR1<\/jats:italic>\n                    correlated with poor survival in two independent clinical cohorts of patients with mCRPC, and a strong positive correlation between\n                    <jats:italic>TGFBR1<\/jats:italic>\n                    and\n                    <jats:italic>ADAM17<\/jats:italic>\n                    expression was observed. In a preclinical human orthotopic mCRPC mouse model, treatment with therapeutic mAbs effectively prevented the nuclear accumulation of T\u03b2RI-ICD, inhibited EMT, and suppressed tumor growth, invasion, and metastasis. Notably, the therapeutic effect was comparable to that of docetaxel, a current standard-of-care chemotherapy, without noticeable side effects on body weight, proximal aorta or heart function detected in immune-deficient mice. These findings suggest that targeting T\u03b2RI cleavage using specific mAbs is a novel precision medicine approach for the treatment of mCRPC. By selectively blocking the prometastatic activity of T\u03b2RI-ICD without disrupting physiological TGF\u03b2 signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02737-x","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:11Z","timestamp":1781650991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting oncogenic T\u03b2RI signaling inhibits androgen-independent prostate cancer growth and metastasis"],"prefix":"10.1038","volume":"11","author":[{"given":"Per","family":"Flodbring Larsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexej","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxiang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4955-9118","authenticated-orcid":false,"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnupriya","family":"Gajavilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Rakhimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelene","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Aripaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Halin Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Huairen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-5821","authenticated-orcid":false,"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Henrik","family":"Heldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6737-7230","authenticated-orcid":false,"given":"Mar\u00e9ne","family":"Landstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2737_CR1","doi-asserted-by":"crossref","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer 149, 778\u2013789 (2021).","DOI":"10.1002\/ijc.33588"},{"key":"2737_CR2","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.7314\/APJCP.2015.16.7.2601","volume":"16","author":"M Esfahani","year":"2015","unstructured":"Esfahani, M., Ataei, N. & Panjehpour, M. Biomarkers for evaluation of prostate cancer prognosis. Asian Pac. J. Cancer Prev. 16, 2601\u20132611 (2015).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2737_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2737_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/1477-3163.83937","volume":"10","author":"PE Lonergan","year":"2011","unstructured":"Lonergan, P. E. & Tindall, D. J. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10, 20 (2011).","journal-title":"J. Carcinog."},{"key":"2737_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He, Y. et al. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal. Transduct. Target Ther. 7, 198 (2022).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2737_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2019.03.001","volume":"75","author":"I Tsaur","year":"2019","unstructured":"Tsaur, I. et al. Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? Cancer Treat. Rev. 75, 20\u201326 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"2737_CR7","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massague","year":"2023","unstructured":"Massague, J. & Sheppard, D. TGF-beta signaling in health and disease. Cell 186, 4007\u20134037 (2023).","journal-title":"Cell"},{"key":"2737_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"2737_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fcell.2020.00605","volume":"8","author":"AF Teixeira","year":"2020","unstructured":"Teixeira, A. F., Ten Dijke, P. & Zhu, H. J. On-target anti-tgf-beta therapies are not succeeding in clinical cancer treatments: What are remaining challenges? Front. Cell Dev. Biol. 8, 605 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2737_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0495-282","volume":"1","author":"V Ivanovic","year":"1995","unstructured":"Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M. & Geliebter, J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat. Med. 1, 282\u2013284 (1995).","journal-title":"Nat. Med."},{"key":"2737_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGFbeta biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2737_CR12","doi-asserted-by":"crossref","unstructured":"Heldin, C. H. & Moustakas, A. Signaling receptors for TGF-beta family members. Cold Spring Harb. Perspect. Biol. 8, a022053 (2016).","DOI":"10.1101\/cshperspect.a022053"},{"key":"2737_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00441-011-1201-y","volume":"347","author":"Y Mu","year":"2012","unstructured":"Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res. 347, 11\u201320 (2012).","journal-title":"Cell Tissue Res."},{"key":"2737_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-beta signaling in health, disease, and therapeutics. Signal. Transduct. Target Ther. 9, 61 (2024).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2737_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41392-023-01711-1","volume":"8","author":"AF Teixeira","year":"2023","unstructured":"Teixeira, A. F., Wang, Y., Iaria, J., Ten Dijke, P. & Zhu, H. J. Simultaneously targeting extracellular vesicle trafficking and TGF-beta receptor kinase activity blocks signaling hyperactivation and metastasis. Signal. Transduct. Target Ther. 8, 456 (2023).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2737_CR16","doi-asserted-by":"crossref","unstructured":"Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-beta family signaling. Sci. Signal. 12, eaav5183 (2019).","DOI":"10.1126\/scisignal.aav5183"},{"key":"2737_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104155","volume":"82","author":"J Song","year":"2022","unstructured":"Song, J. et al. The ubiquitin-ligase TRAF6 and TGFbeta type I receptor form a complex with Aurora kinase B contributing to mitotic progression and cytokinesis in cancer cells. EBioMedicine 82, 104155 (2022).","journal-title":"EBioMedicine"},{"key":"2737_CR18","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1038\/s41388-024-03165-3","volume":"43","author":"Y Mu","year":"2024","unstructured":"Mu, Y. et al. The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells. Oncogene 43, 3321\u20133334 (2024).","journal-title":"Oncogene"},{"key":"2737_CR19","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1080\/15384101.2019.1642069","volume":"18","author":"P Mallikarjuna","year":"2019","unstructured":"Mallikarjuna, P., Raviprakash, T. S., Aripaka, K., Ljungberg, B. & Landstrom, M. Interactions between TGF-beta type I receptor and hypoxia-inducible factor-alpha mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. Cell Cycle 18, 2141\u20132156 (2019).","journal-title":"Cell Cycle"},{"key":"2737_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2009.06.018","volume":"35","author":"C Liu","year":"2009","unstructured":"Liu, C., Xu, P., Lamouille, S., Xu, J. & Derynck, R. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol. Cell 35, 26\u201336 (2009).","journal-title":"Mol. Cell"},{"key":"2737_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1332","volume":"2","author":"Y Mu","year":"2011","unstructured":"Mu, Y. et al. TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun. 2, 330 (2011).","journal-title":"Nat. Commun."},{"key":"2737_CR22","doi-asserted-by":"publisher","first-page":"ra2","DOI":"10.1126\/scisignal.2004207","volume":"7","author":"SK Gudey","year":"2014","unstructured":"Gudey, S. K. et al. TRAF6 stimulates the tumor-promoting effects of TGFbeta type I receptor through polyubiquitination and activation of presenilin 1. Sci. Signal. 7, ra2 (2014).","journal-title":"Sci. Signal."},{"key":"2737_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.18632\/oncotarget.6346","volume":"7","author":"J Song","year":"2016","unstructured":"Song, J. et al. APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta type I receptor intracellular domain. Oncotarget 7, 279\u2013292 (2016).","journal-title":"Oncotarget"},{"key":"2737_CR24","doi-asserted-by":"publisher","first-page":"26783","DOI":"10.1016\/S0021-9258(18)47087-1","volume":"269","author":"S Schultz-Cherry","year":"1994","unstructured":"Schultz-Cherry, S., Lawler, J. & Murphy-Ullrich, J. E. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem. 269, 26783\u201326788 (1994).","journal-title":"J. Biol. Chem."},{"key":"2737_CR25","doi-asserted-by":"publisher","first-page":"7649","DOI":"10.1158\/0008-5472.CAN-11-0833","volume":"71","author":"V Firlej","year":"2011","unstructured":"Firlej, V. et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res. 71, 7649\u20137658 (2011).","journal-title":"Cancer Res."},{"key":"2737_CR26","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2737_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euo.2022.04.004","volume":"5","author":"MD Fenor de la Maza","year":"2022","unstructured":"Fenor de la Maza, M. D. et al. Immune biomarkers in metastatic castration-resistant prostate cancer. Eur. Urol. Oncol. 5, 659\u2013667 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"2737_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymeth.2008.06.014","volume":"45","author":"O Soderberg","year":"2008","unstructured":"Soderberg, O. et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45, 227\u2013232 (2008).","journal-title":"Methods"},{"key":"2737_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/excr.1993.1156","volume":"207","author":"P Franzen","year":"1993","unstructured":"Franzen, P., Ichijo, H. & Miyazono, K. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp. Cell Res. 207, 1\u20137 (1993).","journal-title":"Exp. Cell Res."},{"key":"2737_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 162, 454 (2015).","journal-title":"Cell"},{"key":"2737_CR31","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1038\/s41388-019-0722-9","volume":"38","author":"G Zang","year":"2019","unstructured":"Zang, G., Mu, Y., Gao, L., Bergh, A. & Landstrom, M. PKCzeta facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model. Oncogene 38, 4215\u20134231 (2019).","journal-title":"Oncogene"},{"key":"2737_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"2737_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1593\/neo.07822","volume":"10","author":"SA Tomlins","year":"2008","unstructured":"Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177\u2013188 (2008).","journal-title":"Neoplasia"},{"key":"2737_CR34","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/pros.22482","volume":"72","author":"FL Miles","year":"2012","unstructured":"Miles, F. L., Tung, N. S., Aguiar, A. A., Kurtoglu, S. & Sikes, R. A. Increased TGF-beta1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2\/3 signaling. Prostate 72, 1339\u20131350 (2012).","journal-title":"Prostate"},{"key":"2737_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2737_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/annonc\/mds333","volume":"24","author":"EM de Kruijf","year":"2013","unstructured":"de Kruijf, E. M. et al. The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann. Oncol. 24, 384\u2013390 (2013).","journal-title":"Ann. Oncol."},{"key":"2737_CR37","doi-asserted-by":"crossref","unstructured":"McManus, H. D. et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 28, 672\u2013683 (2024).","DOI":"10.1038\/s41391-024-00906-z"},{"key":"2737_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cell.2008.01.046","volume":"133","author":"D Padua","year":"2008","unstructured":"Padua, D. et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66\u201377 (2008).","journal-title":"Cell"},{"key":"2737_CR39","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti, J. et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 11, 1118\u20131137 (2021).","journal-title":"Cancer Discov."},{"key":"2737_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105212","volume":"105","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine 105, 105212 (2024).","journal-title":"EBioMedicine"},{"key":"2737_CR41","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","volume":"57","author":"J Luo","year":"2025","unstructured":"Luo, J. et al. Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer. Nat. Genet 57, 2468\u20132481 (2025).","journal-title":"Nat. Genet"},{"key":"2737_CR42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"2737_CR43","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"2737_CR44","first-page":"3","volume":"46","author":"EP Neff","year":"2016","unstructured":"Neff, E. P. Models matter in metastasis. Lab Anim. 46, 3 (2016).","journal-title":"Lab Anim."},{"key":"2737_CR45","doi-asserted-by":"crossref","unstructured":"Dominguez, C., McCampbell, K. K., David, J. M. & Palena, C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight 2, e94296 (2017).","DOI":"10.1172\/jci.insight.94296"},{"key":"2737_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep38834","volume":"6","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci. Rep. 6, 38834 (2016).","journal-title":"Sci. Rep."},{"key":"2737_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000101320","volume":"185","author":"MI Kokkinos","year":"2007","unstructured":"Kokkinos, M. I. et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185, 191\u2013203 (2007).","journal-title":"Cells Tissues Organs"},{"key":"2737_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84\u201387 (2013).","journal-title":"Science"},{"key":"2737_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","volume":"57","author":"B Glimelius","year":"2018","unstructured":"Glimelius, B. et al. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol. 57, 187\u2013194 (2018).","journal-title":"Acta Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02737-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:13Z","timestamp":1781650993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02737-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2737"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02737-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L. is a founder, shareholder, and board member of the company MetaCurUm Biotech A.B. that develops T\u03b2RI-based cancer therapies and biomarkers. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}